Hepion Pharmaceuticals, Inc. (HEPA)

Market Cap	2.18M -30.9%
Revenue (ttm)	n/a
Net Income	-2.98M
EPS	-0.26
Shares Out	29.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,237
Open	0.0852
Previous Close	0.0880
Day's Range	0.0750 - 0.0852
52-Week Range	0.0330 - 0.2500
Beta	1.65
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: HEPA